Navamedic

Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all Nordic countries.

Oslo, Norway - 2025.08.13 - Navamedic is pleased to announce that it has

received final approval for the packaging material in national languages for

Norway, Sweden and Denmark, following the earlier announcement on June 27th.

Orion Corporation ("Orion"), the product licensor for Finland and the rest of

the EU, has also obtained final confirmation for the Finnish market.

"We are excited to have received the last approvals, paving the way for our go

-to-market launch in the Nordic region," said Kathrine Gamborg Andreassen, Chief

Executive Officer of Navamedic.

Flexilev® in OraFID® ensures precise and personalized treatment tailored to

individual Parkinson's Patient needs. Medications with a narrow therapeutic

window can benefit from hyper-fractionation, which involves administering

smaller, more frequent doses.

OraFID® is a unique, patented, fully mechanical medical device that dispenses

precise quantities of minitablets with just a few of twists of the hands.

The launch in the Nordic markets is still anticipated in October 2025.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, NavamedicLars Hjarrand, CFO, Navamedic

Mobile: +47 951 78680Mobile: +47 917 62842

About Navamedic

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's

quality of life by being a reliable supplier of high-quality prescription,

consumer health, and hospital products to hospitals and pharmacies. Our growing

product portfolio has been carefully selected to meet current public health

concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to

empower people to live healthier and more fulfilling lives.

What sets us apart is our deep-rooted commitment to understanding the needs and

requirements of the countries where we are present. Our local insight and

competence enable us to understand the specific needs of each country where we

operate and ultimately to gain market access. This makes us a preferred partner

for international companies expanding their footprint across the Nordics and

Benelux regions, through either in-licensing or out-licensing. Navamedic has

been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is

headquartered in Oslo, Norway.

For more information, please visit Navamedic.com

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal